• Skip to main content
  • Skip to footer

EydisBio

  • About Us
  • Technology
    • Pipeline
  • Therapeutic indications
    • Rheumatoid Arthritis
    • Chronic Pain
    • Systemic Sclerosis
  • Our Team
  • Resources
    • Publications
    • FCOI
    • Partners & Funders
  • Contact

Selective TAK1 Inhibitor Development

Targeting autoimmune and inflammatory diseases through the use of highly selective protein kinase inhibitors

Unmet Medical Needs

Utilizing our unique discovery platform, we are developing a pipeline of small molecules targeting TAK1 and other disease-driving proteins to provide safer and more effective treatments for patients suffering from various autoimmune and inflammatory diseases of high unmet need

anti-TNF biologics

40% of patients need
alternatives to anti-TNF
biologics

TAK1 locally blocks

TAK1 locally blocks
TNF signaling at the
site of inflammation

small molecule

As a small molecule,
TAK1 avoids
immune-induced therapy resistance

vivo oral

In vivo oral
bioavailability has been
achieved

vivo efficacy and pilot safety

In vivo efficacy and
pilot safety are in
progress

Review Our Research

Therapeutic Indications

Rheumatoid Arthritis

Targeting underlying inflammation in
the joints of RA patients

More about RA

Chronic Pain

Targeting underlying inflammation driving chronic
inflammatory and neuropathic pain

More about Chronic Pain

Systemic Sclerosis

TAK1 regulates fibroinflammatory
signaling central to SSc

More about SSc

About EydisBio

EydisBio is a small biotech startup based out of Durham, NC focusing on the development of highly selective and potent, novel small molecule kinase inhibitors.

Our current TAK1 program is the first to develop a highly selective orally bioavailable inhibitor of TAK1 for the treatment of inflammatory-mediated diseases. Our proprietary inhibitors represent a novel class of drugs for diseases such as RA, systemic sclerosis, chronic pain, viral-induced ARDS, and SLE.

Read More About Us

About Eydisbio
Timothy Haystead
A word from our president & founder

Timothy Haystead, PhD

Dr. Haystead has extensive experience in all aspects of
small molecule discovery and development. In 2000,
he founded the biotechnology company Serenex, Inc.
which discovered and developed the first orally bioavailable
inhibitor of Hsp90, SNX5422. Read more

Meet Our Team

Stay Up To Date On Our Progress

What's New at Eydisbio

Check Out Our Technology

Read More

Publications and Press Releases

Check Out Our Recent Publications and Press Releases.

Read More

Interested in learning more about
our work or partnering with us?
Reach out to our team!
Asset 1

"*" indicates required fields

GDPR Consent*
This field is for validation purposes and should be left unchanged.

Footer Logo

201 W Main Street, Suite #317, Durham, NC, 27701
Privacy Policy | Web Accessibility. Design by TinyFrog Technologies

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits.
By clicking “Accept”, you consent to the use of ALL the cookies. AcceptReject
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT